scholarly journals Remission of comorbidities, weight loss, and adverse events after Sleeve Gastrectomy and Roux-en-Y gastric bypass in patients with obesity

2021 ◽  
Vol 12 (3) ◽  
pp. 205-217
Author(s):  
Omar Thaher ◽  
Jamal Driouch ◽  
Martin Hukauf ◽  
Christine Stroh
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Adverse Events ◽  
Remission Rate ◽  
P Value ◽  
Extensive Literature ◽  
Treatment Of Obesity ◽  
One Year ◽  
Remission Of Comorbidities

Background: Despite the extensive literature on the outcome and impact of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on comorbidities and weight loss, clear evidence is still lacking. Our study aims to compare the short- and long-term efficacy and safety of the two procedures in patients with obesity. Methods: The primary endpoint of this retrospective registry study is to examine the adverse events after surgery, weight loss, and remission rate of comorbidities 12 months after surgery. Any result with a p-value of 5% corresponds to a significant outcome. Results: 27,882 patients had completed a one-year follow-up. 14,399 patients after SG and 13,483 after RYGB. The overall rate of intraoperative and postoperative complications was not significantly different between the two groups (overall p>5%). The %EWL was 62.4% in the SG group vs. 69.2% in the RYGB group; p<0.001. BMI reduction and mean weight loss were significantly different between the two groups in favor of SG. The RYGB group achieved significantly better remission of diabetes mellitus (T2DM; p<0.001), hypertension (28.8% vs. 23.5%; p < 0.001) and reflux 22.3% vs. 7.8%; p<0.001). Sleep apnea remission was similar between the two groups (10.2%; p<0.001). Conclusion: SG and RYGB are effective methods in the treatment of obesity. RYGB achieved better results in terms of remission of comorbidities and %EWL. However, further studies are needed to investigate the sustainability of weight loss and remission of comorbidities after both procedures.

scholarly journals Remission of comorbidities, weight loss, and adverse events after sleeve gastrectomy and Roux-en-Y Gastric Bypass in patients with obesity

2021 ◽  
Vol 12 (3) ◽  
pp. 251-263
Author(s):  
Omar Thaher ◽  
Jamal Driouch ◽  
Martin Hukauf ◽  
Christine Stroh
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Adverse Events ◽  
Remission Rate ◽  
P Value ◽  
Extensive Literature ◽  
Treatment Of Obesity ◽  
One Year ◽  
Remission Of Comorbidities

Background: Despite the extensive literature on the outcome and impact of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on comorbidities and weight loss, clear evidence is still lacking. Our study aims to compare the short- and long-term efficacy and safety of the two procedures in patients with obesity. Methods: The primary endpoint of this retrospective registry study is to examine the adverse events after surgery, weight loss, and remission rate of comorbidities 12 months after surgery. Any result with a p-value of ≤ 5% corresponds to a significant outcome. Results: 27,882 patients had completed a one-year follow-up. 14,399 patients after SG and 13,483 after RYGB. The overall rate of intraoperative and postoperative complications was not significantly different between the two groups (overall p>5%). The %EWL was 62.4% in the SG group vs. 69.2% in the RYGB group; p<0.001. BMI reduction and mean weight loss were significantly different between the two groups in favor of SG. The RYGB group achieved significantly better remission of diabetes mellitus (T2DM; p<0.001), hypertension (28.8% vs. 23.5%; p < 0.001) and reflux 22.3% vs. 7.8%; p<0.001). Sleep apnea remission was similar between the two groups (10.2%; p<0.001). Conclusion: SG and RYGB are effective methods in the treatment of obesity. RYGB achieved better results in terms of remission of comorbidities and %EWL. However, further studies are needed to investigate the sustainability of weight loss and remission of comorbidities after both procedures.

PL-312: Laparoscopic Roux-en-Y gastric bypass achieves greater weight loss than sleeve gastrectomy after one year

2010 ◽  
Vol 6 (3) ◽  
pp. S24
Author(s):  
Arezou Yaghoubian ◽  
Amy Tolan ◽  
Bruce E. Stabile ◽  
Amy H. Kaji ◽  
Gary Belzberg ◽  
...  
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
One Year

scholarly journals Fat-Free Mass and Skeletal Muscle Mass Gain Are Associated with Diabetes Remission after Laparoscopic Sleeve Gastrectomy in Males but Not in Females

2022 ◽  
Vol 19 (2) ◽  
pp. 978
Author(s):  
Ngan Thi Kim Nguyen ◽  
Nguyen-Phong Vo ◽  
Shih-Yi Huang ◽  
Weu Wang
Keyword(s):  
Skeletal Muscle ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Laparoscopic Sleeve Gastrectomy ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Remission Rate ◽  
Fat Free Mass ◽  
Post Operation ◽  
One Year

Besides massive body weight loss, laparoscopic sleeve gastrectomy (LSG) causes massive lean mass, including fat-free mass (FFM) and skeletal muscle mass (SM) that present higher metabolic rates in males. This study examines sex differences in FFM and SM changes of type 2 diabetes (T2D) remission at 12 months post-LSG. This cohort study recruited 119 patients (53.7% females) with T2D and obesity (body mass index 42.2 ± 7.0 kg/m2) who underwent LSG. Fat-mass (FM) loss was higher in males than in females (−12.8 ± 6.2% vs. −9.9 ± 5.0%, p = 0.02) after one-year post-operation. Regardless of the weight-loss difference, males had higher FFM and SM gain than did females (12.8 ± 8.0 vs. 9.9 ± 5.0% p = 0.02 and 6.5 ± 4.3% vs. 4.9 ± 6.2%, p = 0.03, respectively). Positive correlations of triglyceride reduction with FM loss (r = 0.47, p = 0.01) and SM gain (r = 0.44, p = 0.02) over 12 months post-operation were observed in males who achieved T2D remission. The T2D remission rate significantly increased 16% and 26% for each additional percentage of FFM and SM gain one year after LSG, which only happened in males. Increased FFM and SM were remarkably associated with T2D remission in males, but evidence lacks for females.

Weight loss at one year after sleeve gastrectomy compared to gastric bypass

Appetite ◽  
2015 ◽  
Vol 87 ◽  
pp. 388
Author(s):  
A. Abeysekera ◽  
A. Head ◽  
M. Labib
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
One Year

scholarly journals Long-Term Weight Loss Results, Remission of Comorbidities and Nutritional Deficiencies of Sleeve Gastrectomy (SG), Roux-En-Y Gastric Bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB) on Type 2 Diabetic (T2D) Patients

2020 ◽  
Vol 17 (20) ◽  
pp. 7644
Author(s):  
Maria-Jose Castro ◽  
Jose-Maria Jimenez ◽  
Miguel-Angel Carbajo ◽  
Maria Lopez ◽  
Maria-Jose Cao ◽  
...  
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
The Other ◽  
Nutritional Deficiencies ◽  
Remission Of Comorbidities ◽  
Type 2 Diabetic

This study aimed to compare the long-term weight loss results, remission of comorbidities and nutritional deficiencies of sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB) and One-Anastomosis gastric bypass (OAGB) on type 2 diabetic (T2D) patients. Patients and Methods: A retrospective analysis of all the morbidly obese and diabetic patients undergoing SG, RYGB, and OAGB as primary bariatric procedures between February 2010 and June 2015 was performed. Anthropometric parameters, remission of comorbidities, nutritional deficiencies and supplementation requirements at 1, 2 and 5 years’ follow-up were monitored. Patients lost to follow-up 5 years after surgery were excluded from the analysis. Results: 358 patients were included. The follow-up rate was 84.8%. Finally, 83 SG, 152 RYGB, and 123 OAGB patients were included in the analysis. OAGB obtained significantly greater weight loss and remission of dyslipidemia than the other techniques. There was a trend towards greater T2D and hypertension remission rate after OAGB, while fasting glucose and glycated hemoglobin levels were significantly lower after OAGB. There were no significant differences in hemoglobin or protein levels between groups. SG obtained lower iron deficiencies than the other techniques, while there were no significant differences in other nutritional deficiencies between groups. Conclusion: OAGB obtained greater weight loss and remission of dyslipidemia than RYGB or SG. Excluding lower iron deficiency rates after SG, there were no significant differences in the development of nutritional deficiencies between groups.

scholarly journals Effects of sleeve gastrectomy versus omega-loop gastric bypass. What is best for weight loss, perioperative adverse events, and comorbidities?

2021 ◽  
Vol 12 (2) ◽  
pp. 219-231
Author(s):  
Omar Thaher ◽  
Jamal Driouch ◽  
Martin Hukauf ◽  
Christine Stroh
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Perioperative Complications ◽  
Omega Loop Gastric Bypass ◽  
Significant Difference ◽  
Omega Loop ◽  
One Year ◽  
Remission Of Comorbidities ◽  
Loop Gastric Bypass

Aim of the study: This study investigated whether Sleeve Gastrectomy (SG) or Omega-Loop-Gastric-Bypass (OAGB) has the best benefit in weight loss, perioperative risk, and remission of comorbidities. Methods: 29,407 patients after SG and OAGB were included in the German Bariatric Surgery Registry (GBSR). Outcome criteria were perioperative morbidity, perioperative complications, and remission of comorbidities after one year of follow-up. Results: 15,169 patients had completed 1-year follow-up (770 patients after OAGB and 14,399 after SG). The %EWL was higher for OAGB than for SG (70.4 ± 18.5 for OAGB and 62.4 ± 22.6 for SG; p<0.001). BMI reduction was also a significant difference in favor of OAGB (17.5 ± 5.6 kg/m2 for OAGB vs. 15.5 ± 5.9 for SG; p<0.001). There was no significant difference between the two groups in perioperative complications (p<5%). Significant differences in favor of OAGB were found in remission of hypertension (p<0.001), IDDM (p<0.001), NIDDM (p<0.001), reflux (p<0.001), and sleep apnea (p<0.001). Conclusion: Our analysis showed that OAGB surgery was associated with more significant BMI reduction and weight loss one year after surgery. In addition, OAGB surgery was significantly more effective in improving obesity-related comorbidities. Our results support the performance of OAGB over SG in patients with obesity and comorbidities. However, the contraindications and general condition of the patient should be considered in the context of this.

scholarly journals One Year Follow-up Results after Sleeve Gastrectomy in Type 2 Diabetes Mellitus Patients with Morbid Obesity

2016 ◽  
Vol 23 (2) ◽  
pp. 191-199
Author(s):  
Viorel Dejeu ◽  
Dănuţ-Aurel Dejeu ◽  
Paula Dejeu ◽  
Aurel Babeş
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Laparoscopic Sleeve Gastrectomy ◽  
Remission Rate ◽  
Glycosylated Hemoglobin ◽  
Diabetes Remission ◽  
One Year

AbstractBackground and aims: Bariatric surgery has been shown to be superior to nonsurgical approaches in terms of weight loss and remission of type 2 diabetes (T2DM) and metabolic syndrome. This prospective, single-center, follow-up study assessed percentage of excessive weight loss (%EWL), glycosylated hemoglobin (HbA1c) levels, prescribed antidiabetes drugs and diabetes remission rates in obese T2DM patients who underwent laparoscopic sleeve gastrectomy.Materials and methods: 81 patients were selected and data recorded preoperatively, 3, 6 and 12 months postoperatively.Results: We recorded - 69.3% EWL at 12 months (p<0.0001 compared to baseline) and a fall of HbA1c from 8.1±2.6% to 6.7±2.8% at 12 months postoperatively (p<0.0001). The percentage of patients with HbA1c<6.5% showed an increase to 40.7% (p=0.0004) and the one year T2DM remission rate was 20.9% (p=0.0012).Conclusions: Laparoscopic sleeve gastrectomy can significantly reduce the BMI, with near 70% EWL and near 21% T2DM remission rate in 1 year.

Sign in / Sign up

Export Citation Format

Share Document